P03951 (FA11_HUMAN) Homo sapiens (Human)

Coagulation factor XI UniProtKBInterProSTRINGInteractive Modelling

625 aa; Sequence (Fasta) ; (Isoform 2)

Available Structures

114 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
human recombinant coagulation FXI in complex with a peptide derived from human high molecular weigh…
5i25
 Heteromer
P01042; 		19-623
3×NAG;
Assess
Factor XI and Plasma Kallikrein apple domain structures reveals different kininogen bound complexes
7qot
 Heteromer
P01042; 		20-374
2×NAG; 3×SO4;
Assess
Factor XIa in complex with the inhibitor 4-{2-[(1S)-1-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}a…
4ty6
 Heteromer
380-625
1×39D; 1×SO4; 8×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(6R)-6-(3-chlorophenyl)-2-oxo-1,3-oxazi…
5qqo
 Heteromer
380-625
1×NRJ; 1×SO4; 12×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazo…
4x6n
 Heteromer
380-625
1×3Y5; 1×SO4; 11×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-y…
5q0f
 Heteromer
380-625
1×9FA; 2×SO4; 12×EDO;
Assess
Crystal Structure of the FXIa Catalytic Domain in Complex with EcotinM84R
1xx9
 Heteromer
P23827; 		388-625
1×NAG;
Assess
Crystal Structure of the FXIa Catalytic Domain in Complex with mutated Ecotin
1xxd
 Heteromer
P23827; 		388-625
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Kunitz Protease …
1zjd
 Heteromer
P05067; 		388-624
Assess
Crystal Structure of the FXIa Catalytic Domain in Complex with Ecotin Mutant (EcotinP)
1xxf
 Heteromer
P23827; 		388-624
2×NA;
Assess
FXIa antibody complex
6aod
 Heteromer
388-623
4×SO4; 9×GOL; 3×CO; 5×PO4;
Assess
Allosteric Inhibition as a new mode of Action for BAY 1213790, a Neutralizing Antibody Targeting th…
6hhc
 Heteromer
388-623
3×SO4; 1×DMS;
Assess
COAGULATION FACTOR XI CATALYTIC DOMAIN IN COMPLEX WITH FAB-PORTION OF MAA868
6r8x
 Heteromer
392-623
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4cre
homo-3-mer388-625
3×MVN; 24×SO4;
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4crg
homo-3-mer388-624
12×GOL; 3×J4X; 12×SO4;
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4crd
homo-3-mer388-623
3×OTJ; 9×SO4;
Assess
Allosteric activation of human prekallikrein by apple domain disc rotation
6i58
homo-2-mer20-623
2×NAG; 10×CL; 2×PEG; 4×NAG;
Assess
Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Double Brid…
6twc
homo-2-mer379-625
2×ACN;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XIa in Complex with Double Bridged …
6twb
homo-2-mer379-625
3×NH4;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phe…
5qtx
homo-2-mer380-625
1×QLD; 2×SO4; 13×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[1-(3-chloro-2-fluorophenyl)-5-methyl-1…
5qtu
homo-2-mer380-625
1×QEV; 1×SO4; 9×EDO;
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4cr9
homo-2-mer388-625
2×OTW; 12×SO4;
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4cr5
homo-2-mer388-625
2×0TU; 14×SO4;
Assess
Solution Structure of the A4 Domain of Blood Coagulation Factor XI
2j8j
homo-2-mer290-379
Assess
FXI Apple 4 domain loop-out conformation
2j8l
homo-2-mer290-379
Assess
Human Plasma Coagulation Factor XI in complex with peptide P39
5eok
monomer20-623
1×NAG; 3×NAG;
Assess
Human Plasma Coagulation FXI with peptide LP2
5eod
monomer20-623
3×NAG;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR ((15S)-18-CHLORO- 15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-Y…
5tks
monomer388-625
1×7DL; 1×SO4; 15×EDO;
Assess
Crystal structure of Factor XIa in complex with Clavatadine A
3bg8
monomer388-625
1×G0R; 1×BEN; 5×SO4;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S43…
1zhr
monomer388-625
1×BEN;
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4cra
monomer388-625
2×GOL; 1×XJ8; 3×SO4;
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4crb
monomer388-625
2×GOL; 1×7P0; 4×SO4;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR ethyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phe…
5qty
monomer388-625
1×QLJ; 2×SO4; 13×EDO;
Assess
Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tet…
4y8x
monomer388-625
1×4GR; 2×SO4; 9×EDO;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with N-(7-Carbamimido…
1zsj
monomer388-625
1×SO4; 1×BCT; 1×709;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 6-Carbamimidoyl-…
1zsk
monomer388-625
2×SO4; 1×BCT; 1×421;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((10R,14S)- 14-(4-(3-CHLORO-2,6-DIFLUOROPHENYL)-6-O…
6w50
monomer388-625
1×SWP; 2×SO4; 12×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(5E,8S)-8-[(4S)-4-(3-chlorophenyl)-2-oxopiperidin-…
5qqp
monomer388-625
1×NR7; 1×SO4; 8×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[(N-{(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-…
5e2o
monomer388-625
1×5JM; 2×SO4; 9×EDO;
Assess
Factor XIa in complex with the inhibitor (2S)-6-amino-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)-5-chlo…
4ty7
monomer388-625
1×39F; 2×SO4; 7×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]c…
5exm
monomer388-625
1×5ST; 2×SO4; 5×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (4-{4-chloro-2-[(1S)-1-({3-[5-chloro-2-(1H-tetrazol…
4x6o
monomer388-625
1×3Y4; 2×SO4; 9×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1…
5qcl
monomer388-625
1×BUY; 1×SO4; 10×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]et…
5e2p
monomer388-625
1×7P0; 1×SO4; 10×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((12E,15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-Y…
5tkt
monomer388-625
1×7DS; 2×SO4; 11×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl (2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)ph…
5qtw
monomer388-625
1×QLM; 2×SO4; 14×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phen…
5q0d
monomer388-625
1×9EY; 2×SO4; 13×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4S,8S)-8-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)p…
5q0e
monomer388-625
1×9FD; 2×SO4; 15×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((15S)-15-(((2E)-3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PH…
5tku
monomer388-625
1×7DK; 2×SO4; 10×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(2R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)p…
5qtv
monomer388-625
1×QLS; 2×SO4; 13×EDO;
Assess
Factor XIa in complex with the inhibitor (2E)-N-[(1S)-1-[5-chloro-4-(4-hydroxy-2-oxo-1,2-dihydroqui…
4y8z
monomer388-625
1×4CE; 1×SO4; 5×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[[(1~{S})-2-[(~{E})-3-[3-chloranyl-2-fluora…
5qcm
monomer388-625
1×BVJ; 1×SO4; 15×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-{[5-amino-1-(3-chloro-2-fluorophenyl)-1H…
5qtt
monomer388-625
1×QEY; 1×SO4; 11×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1…
5qcn
monomer388-625
1×BVM; 1×SO4; 15×EDO;
Assess
Factor XIa in complex with the inhibitor 5-aminocarbonyl-2-[3-[(2s,4r)-6-carbamimidoyl-4-methyl-4-p…
4na8
monomer388-625
1×1T6; 1×SO4; 2×EDO;
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4crf
monomer388-625
3×GOL; 1×R9B; 4×SO4; 1×CL;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indaz…
5exl
monomer388-625
1×5SS; 2×SO4; 7×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(11S)-11-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)ph…
5wb6
monomer388-625
1×9ZM; 1×SO4; 14×EDO;
Assess
Factor XIA in complex with the inhibitor methyl (4-{6-[(1S)-2-[(3R)-1-acetylpiperidin-3-yl]-1-({(2E…
6c0s
monomer388-625
1×EEJ; 1×SO4; 12×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-amino-1H-indazol-6-yl)-5-chloro-1H-imidazo…
4x6m
monomer388-625
1×3Y3; 1×SO4; 9×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(4R,5E,8S)-11-chloro-8-[(2,6-difluoro-4-methylbenz…
5q0h
monomer388-625
1×9F1; 2×SO4; 8×EDO;
Assess
Factor XIa in complex with the inhibitor methyl (4-{4-chloro-2-[(1S)-1-({(2E)-3-[5-chloro-2-(1H-tet…
4y8y
monomer388-625
1×4D5; 2×SO4; 7×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl [(3R,7S)-7-({(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)p…
5q0g
monomer388-625
1×9F7; 1×SO4; 5×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR trans-N-{(1S)-1-[4-(3-amino-2H-indazol-6-yl)pyridin-2-yl]-…
4wxi
monomer388-625
1×3VM; 2×SO4; 2×EDO;
Assess
FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S},3~{R})-1-[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetr…
5qck
monomer388-625
1×BUV; 1×SO4; 3×EDO;
Assess
Factor XIA in complex with the inhibitor 3'-[(2S,4R)-6-carbamimidoyl-4-methyl-4-phenyl-1,2,3,4-tetr…
4na7
monomer388-625
1×1T5; 3×SO4;
Assess
FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR Milvexian (BMS-986177), I…
7mbo
monomer388-624
1×NAG; 1×YXG;
Assess
COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 2
8bo6
monomer388-624
1×QW0; 1×CIT; 4×GOL;
Assess
FACTOR XIA (C500S [C122S]) IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[(~{E})-3-[5…
5exn
monomer388-624
1×NAG; 1×5SU;
Assess
Creating novel F1 inhibitors through fragment based lead generation and structure aided drug design
4crc
monomer388-624
1×OTM; 1×SO4;
Assess
Factor XIa in Complex with Compound 2a
7v0z
monomer388-624
1×OQ6;
Assess
Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Benzamidine…
1zhm
monomer388-624
1×BEN; 1×GSH;
Assess
Crystal Structure of the Catalytic Domain of Factor XI in complex with 4-(guanidinomethyl)-phenylbo…
1zmj
monomer388-624
2×SO4; 1×HDB; 1×TRS;
Assess
Crystal Structure of the Catalytic Domain of Human Coagulation Factor XIa in Complex with alpha-Ket…
2fda
monomer388-624
2×BCT; 1×SO4; 1×682;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with (R)-1-(4-(4-(hyd…
1zmn
monomer388-624
3×SO4; 1×427;
Assess
Factor XI complexed with a pyrimidinone inhibitor
1zsl
monomer388-624
1×624;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Benzylamino…
1ztj
monomer388-624
2×SO4; 1×BCT; 1×632;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 4-Methyl-pentano…
1zpb
monomer388-624
1×SO4; 1×995;
Assess
Crystal Structure of the Catalytic Domain of Factor XI in complex with (R)-1-(4-(4-(hydroxymethyl)-…
1zml
monomer388-624
6×SO4; 1×BCT; 1×412;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with a peptidomimetic…
1zom
monomer388-624
1×SO4; 1×339;
Assess
Factor XI complexed with 3-hydroxypropyl 3-(7-amidinonaphthalene-1-carboxamido)benzenesulfonate
1zrk
monomer388-624
3×SO4; 1×367;
Assess
Factor XI catalytic domain complexed with 2-guanidino-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-…
1zlr
monomer388-624
3×SO4; 1×368; 1×GOL;
Assess
Factor XI catalytic domain complexed with N-((R)-1-(4-bromophenyl)ethyl)urea-Asn-Val-Arg-alpha-keto…
1zpz
monomer388-624
1×SO4; 1×BUK;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Amino-6-oxo…
1ztk
monomer388-624
2×SO4; 1×62A;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-[2-(3-Chloro-p…
1zpc
monomer388-624
3×SO4; 1×716;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with N-[4-Guanidino-1…
1ztl
monomer388-624
2×SO4; 1×737;
Assess
Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S43…
1zhp
monomer388-624
1×BEN; 1×GSH;
Assess
Coagulation factor XI protease domain in complex with active site inhibitor
6ts4
monomer388-623
3×SO4; 5×DMS; 1×NA; 1×J7B;
Assess
COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 34
8bo7
monomer388-623
1×QW6; 1×CIT; 1×TRS;
Assess
COAGULATION FACTOR XI CATALYTIC DOMAIN (C123S) IN COMPLEX WITH NVP-XIV936
6usy
monomer388-623
1×QGS;
Assess
Coagulation factor XI protease domain in complex with active site inhibitor
6ts5
monomer388-623
1×NW2; 3×SO4; 2×DMS;
Assess
Coagulation factor XI protease domain in complex with active site inhibitor
6ts6
monomer388-623
3×SO4; 3×DMS; 1×NW5;
Assess
Factor XIa in Complex with Compound 2e
7v11
monomer388-623
1×OQO; 1×CIT;
Assess
Factor XIa in Complex with Compound 2j
7v16
monomer388-623
1×CIT; 1×OT7;
Assess
Factor XIa in Complex with Compound 2k
7v17
monomer388-623
1×CIT; 1×OTL;
Assess
Factor XIa in Complex with Compound 2g
7v13
monomer388-623
1×CIT; 1×ORF;
Assess
Factor XIa in complex with compound 7
6vlu
monomer388-623
1×CIT; 1×R2Y;
Assess
Human FXIa in complex with small molecule inhibitors.
4d7f
monomer388-623
1×GOL; 1×IXA; 4×SO4;
Assess
Factor XIa in Complex with Compound 2f
7v12
monomer388-623
1×OR0; 1×CIT;
Assess
Factor XIa in Complex with Compound 2i
7v15
monomer388-623
1×CIT; 1×OSX;
Assess
Factor XIa in Complex with Compound 2h
7v14
monomer388-623
1×CIT; 1×ORU;
Assess
COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 3
8bo5
monomer388-623
1×QVO; 1×CIT; 2×GOL;
Assess
Factor XIa in complex with compound 11
6vlv
monomer388-623
2×FLC; 1×R3A;
Assess
Factor XIa in Complex with Compound 3f
7v18
monomer388-623
1×CIT; 1×OTX;
Assess
COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR 1
8bo4
monomer388-623
1×GOL; 1×QVI;
Assess
Human FXIa in complex with small molecule inhibitors.
4d76
monomer388-623
3×GOL; 1×J1J; 3×SO4;
Assess
Factor XIa in Complex with Compound 2d
7v10
monomer388-623
1×OQI; 1×CIT;
Assess
Factor XIa in complex with a clorophenyl-tetrazole inhibitor
3sor
monomer388-623
1×CIT; 1×O58;
Assess
COAGULATION FACTOR XI PROTEASE DOMAIN IN COMPLEX WITH ACTIVE SITE INHIBITOR Asundexian
8bo3
monomer388-623
1×QV3; 1×CIT;
Assess
FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR (2E)-N-{(1S)-1-[4-(3-amin…
4x6p
monomer388-623
1×NAG; 1×3YU; 1×CIT; 1×GOL;
Assess
Human FXIa in complex with small molecule inhibitors.
4d7g
monomer388-623
6×GOL; 1×E6U; 5×SO4; 1×TRS;
Assess
Benzothiazinone inhibitor in complex with FXIa
3sos
monomer388-623
1×CIT; 1×TRS; 1×O61;
Assess
Coagulation factor XI protease domain in complex with active site inhibitor
6ts7
monomer388-623
1×NWE;
Assess
The crystal structure of FXIa serine protease domain in complex with benzamidine
7cj1
monomer388-623
1×BEN;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6i58.1.Amonomer0.8220-623
100.00
Assess

1 SWISS-MODEL model built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 26i58.1.Amonomer0.7820-569
99.64
Assess